Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies.
Hunter SF, Aburashed RA, Alroughani R, Chan A, Dive D, Eichau S, Kantor D, Kim HJ, Lycke J, Macdonell RAL, Pozzilli C, Scott T, Sharrack B, Wiendl H, Chung L, Daizadeh N, Baker DP, Vermersch P; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators.
Hunter SF, et al. Among authors: aburashed ra.
Neurol Ther. 2021 Dec;10(2):803-818. doi: 10.1007/s40120-021-00262-3. Epub 2021 Jun 24.
Neurol Ther. 2021.
PMID: 34165694
Free PMC article.